Aileron Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
RNTX$0.59-5.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(21,902) | $(8,393) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization expense | 63 | 67 |
| Net amortization of premiums and discounts on investments | — | (156) |
| Stock-based compensation expense | 984 | 920 |
| Gain on sale of property and equipment | — | (42) |
| Loss on disposition of property and equipment | — | 16 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (89) | (93) |
| Other assets | 2,191 | 24 |
| Accounts payable | (111) | (1,236) |
| Operating lease liabilities | (48) | (33) |
| Accrued expenses and other current liabilities | 1,433 | (491) |
| Net cash used in operating activities | (17,479) | (9,417) |
| Cash flows from investing activities: | ||
| Proceeds from sale of property and equipment | — | 42 |
| Proceeds from sales or maturities of investments | — | 16,250 |
| Net cash provided by investing activities | — | 16,292 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock, net of offering costs | 10,645 | — |
| Proceeds from issuance of common stock in connection with stock option exercises | 142 | — |
| Proceeds from issuance of warrants, net of offering costs | 7,030 | — |
| Net cash provided by financing activities | 17,817 | — |
| Effect of exchange rate changes on cash and cash equivalents | 1 | — |
| Net increase in cash, cash equivalents and restricted cash | 339 | 6,875 |
| Cash, cash equivalents and restricted cash at beginning of period | 17,338 | 5,219 |
| Cash, cash equivalents and restricted cash at end of period | $17,677 | $12,094 |
| Cash and cash equivalents at end of period | $17,652 | $12,069 |
| Restricted cash at end of period | 25 | 25 |
| Cash, cash equivalents and restricted cash at end of period | $17,677 | $12,094 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Conversion of Series X non-voting convertible preferred stock into common stock shares | $46,405 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.